DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.
Momeny M, Tienhaara M, Sharma M, Chakroborty D, Varjus R, Takala I, Merisaari J, Padzik A, Vogt A, Paatero I, Elenius K, Laajala TD, Kurppa KJ, Westermarck J.
Momeny M, et al. Among authors: sharma m.
EMBO Mol Med. 2024 Jun 17. doi: 10.1038/s44321-024-00088-0. Online ahead of print.
EMBO Mol Med. 2024.
PMID: 38886591
Free article.